Learning Hub

Welcome to our collaborative initiative, a dedicated networking subpage showcasing the synergistic efforts of innovative projects. iPROLEPSIS networking activities Our shared vision is to establish a robust ecosystem of initiatives , where the combined strength of each project contributes to the overarching goal of advancing healthcare and well-being. By pooling our resources, knowledge, and expertise, we believe in the potential for significant benefits both for the collaborative cluster and the individual projects involved. Networking projects funded under the call HORIZON-HLTH-2022-STAYHLTH-02-01 CARE-IN-HEALTH Cardiovascular REsolution of INflammation to promote HEALTH WEBSITE Cardiovascular diseases (CVD) are the leading cause of mortality in Europe (1.9 million of annual deaths). CVD are significant public health challenge, accounting for €200 billion in economic burden annually in Europe. Lipid-mediated chronic inflammation and particularly the failure in the resolution of the inflammation, is a particular critical risk factor for the transition from health to CVD. CARE-IN-HEALTH addresses this by aiming to identify the pathways involved in the resolution of the lipid-mediated inflammation to prevent and reverse inflammation and therefore CVD. The interdisciplinary consortium will collect and integrate epidemiological, multi-omics, and immune data to create the CARE-IN-HEALTH Atlas, which will be openly accessible to the scientific community. Such a knowledge base will allow to systematically identify and validate individual’s critical immune pathways. A CARE-IN-HEALTH MCDSS (multi-criteria decision support system) will guide healthcare professionals to design personalised CVD prevention strategies. The CARE-IN-HEALTH BIOSENSOR will monitor inflammation resolution for citizens. CARE-IN-HEALTH will demonstrate proof-of-concept for an appropriate lipid intake as dietary intervention and specifically, for the use of vegetal omega-3 fatty acid sources as substrates for immunomodulatory lipid mediators and resolution of inflammation. All this is based on the results of a proof-of-concept clinical trial. GlycanTrigger Glycans as master triggers of health to intestinal inflammation transition WEBSITE GLYCANTRIGGER - Glycans as master triggers of health to intestinal inflammation transition. The GlycanTrigger project proposes a thorough and innovative approach to understand better the health-to-chronic inflammation transition occurring in patients with Crohn’s Disease that will be translated into improved disease prediction and prevention. The project will address how changes in glycosylation of the gut mucosa act as a primary event that dysregulates not only local mechanisms but also systemic mechanisms, involving the novel concept of glycan mimicry as an early trigger of the health-to-inflammation transition. The long-term goal of this project is to unlock a new checkpoint that regulates the transition to chronic inflammation, aiming to figure out how to turn off this process by developing novel preventive intervention strategies. halt-RONIN Discovering chronic inflammation biomarkers that define key stages in the Healthy-to-NASH (non-alcoholic steatohepatitis) transition to inform early prevention and treatment strategies. Downolad PDF to read more. WEBSITE NAFL (non-alcoholic fatty liver) is the most widespread subtype of NAFLD, a highly prevalent inflammation-related disease, characterized by steatosis, relatively benign and reversible condition, which can progress to the more serious progressive stage of non-alcoholic steatohepatitis (NASH), in which steatosis is accompained by lipotoxicity, mitochondrial dysfunction and a high state of inflammation and fibrosis. IMMEDIATE Imminent Disease Prediction and Prevention at the Environment Host Interface WEBSITE The EU-funded research project IMMEDIATE strives to identify individual biomarkers of risk and resilience against chronic inflammation by investigating the diet-microbiome-metabolite-immune axis. This complex interaction refers to how an individual's diet, gut microbiota, metabolites, and immune system can influence their health. IMMEDIATE will use cutting-edge technologies and clinical and metadata from large observational cohort studies to identify pre-disease stages and further our understanding of the mechanisms and molecular pathways underpinning non-communicable diseases. Furthermore, a proof-of-concept study on healthcare professionals will be conducted to test the effectiveness of a probiotic intervention and ultimately develop mobile apps designed to offer personalized lifestyle recommendations and empower citizens to manage their own health proactively. INITIALISE Inflammation in human early life: targeting impacts on life-course health WEBSITE INITIALISE (Inflammation in human early life: targeting impacts on life-course health) is an EU funded project that aims to elucidate how exposures and genome impact gut microbiome, host immune system and metabolism, and how the interplay of these factors impact life-course health.  INITIALISE aims to define the role of the maturation of the immune system as a mediator between exposures and life-course health. INTERCEPT-T2D Early Interception of Inflammatory-mediated Type 2 Diabetes WEBSITE Inflammatory-based interceptive medicine in type 2 diabetes Individuals with type 2 diabetes (T2D) do not use insulin efficiently and, therefore, their glucose levels rise. T2D is a heterogeneous disease, which is an obstacle to the delivery of an optimal tailored treatment. Consequently, patients’ individual trajectories of progressive hyperglycaemia and risk of chronic complications such as stroke, heart attacks, nephropathy and retinopathy are so far difficult to predict. Chronic systemic inflammation has been suggested to be a major contributor to the onset and progression of T2D complications. The EU-funded INTERCEPT-T2D project will bring a new and clinically relevant dimension in T2D care considering at diagnosis inflammatory parameters that are of importance for the transition to T2D-related complications. Moreover, the project will help deliver optimal treatments tailored to patient needs and conduct a clinical trial to evaluate the efficacy of anti-inflammatory strategies. miGut-Health Personalised blueprint intestinal health WEBSITE The miGut-Health project is an EU-funded initiative that is developing novel strategies to predict and prevent inflammatory bowel disease (IBD). miGut-Health aims to create personalised patient engagement strategies for predicting and monitoring preclinical IBD by focusing on the transitory phase from health to disease. The overarching goal is to provide strategies for early disease prediction, prevention and gut health improvement for people affected by IBD, high-risk individuals and citizens. AIDA An Artificially Intelligent Diagnostic Assistant for gastric inflammation WEBSITE Most cases of gastric cancer (GC) are detected at a late stage, when patients have a median life expectancy of about a year. Diagnosing people at risk of developing GC at the pre-symptomatic stage, typically chronic gastric inflammation, could significantly improve the outlook. Artificial intelligence (AI) can help clinicians make sense of their own data by automating much of the treatment and analysis, which require manual work and years of experience. But it can do more: it can bring together available data from various sources into a vast data lake and cross-correlate the data to derive a ‘risk score’ for gastric cancer and shed light on the mechanisms of its evolution. Aida aims to do just that. It helps researchers understand the mechanisms that trigger gastric oncogenesis, helps clinicians diagnose precancerous inflammation at the earliest possible stage, suggests personalised therapeutic strategies for treatment and follow-up, and makes personalised recommendations for monitoring patient health status, thus contributing to gastric cancer prevention. This places Aida squarely on Europe’s agenda of ‘Staying healthy in a rapidly changing society’. Aida unites some of Europe’s leading authorities in the field of gastric inflammation, gastric cancer, leading AI and machine learning experts, experts on data governance and privacy, representatives of the public administration and patient advocates. Aida also has strong ties with the industry. After the project, the results will live on in a foundation that acts as a transnational focal point for chronic gastric inflammation — and GC in general. We hope that the solid, inclusive design principles of Aida, its societal relevance and its durability will spawn a vigorous ecosystem around chronic gastric inflammation, its understanding and its treatment. And we hope that it will inspire other data collaboratives in health — for other chronic inflammations, other forms of cancer or other ailments altogether. PROTO Advanced Personalized Therapies for Osteoarthritis WEBSITE Osteoarthritis (OA) is a chronic progressive joint disorder, characterized by inflammation causing pain, stiffness, swelling and gradual loss of joint function. PROTO aims to halt and partially reverse the structural and functional changes caused by inflammatory processes in OA Our ambitious goal is to introduce: a highly innovative anti-inflammatory local placental derived cell therapy in early-stage OA patients and a personalized sensor-based training intervention intended to prevent inflammation and OA onset during a crucially important ‘window of opportunity’ by correcting pathological movement patterns in pre-stage OA patients. ENDOTARGET Sytemic Endotoxemia as the driver of chronic inflammation–Biomarkers and novel therapeutic targets for Arthritis WEBSITE ENDOTARGET explores the relationship between gut microbiota, gut permeability, and systemic endotoxemia with a special focus on the three most abundant rheumatic diseases (RDs): osteoarthritis, rheumatoid arthritis and spondylarthritis. The aim is to clarify (1) the role of the three factors gut microbiota, gut permeability and systemic endotoxemia in RD onset and pathogenesis, (2) which events and mechanisms are responsible for the origin of RDs, and (3) the influence of the gut microbiota on the joints. Based on the gained knowledge, e.g. new biomarkers for risk assessment will be identified and a Rheumatic disease risk prediction tool (RDPT) will be developed to support clinicians in the classification of patients and to treat RDs preventively. This tool will help to reduce the risk of RD onset and/or to reduce disease activity. PRAESIIDIUM Real-time prediction of the prediabetes risk WEBSITE PRAESIIDIUM will develop a tool based on artificial intelligence coupled with multi-scale, multi-organ integrated mathematical equations for the real-time prediction of the prediabetes risk of an individual. The prediction algorithm will draw on a rich set of information for training, derived from prior clinical data, the individual’s family history, and a pilot study testing wearable sensors that will provide glucose, bioimpedance, and heart rate monitoring. The PRAESIIDIUM platform will be made available to healthcare professionals and patients for an easier data entering and results query and it will be linked to common wearable sensors to monitor the physical activity. PREVALUNG EU Biomarkers affecting the transition from cardiovascular disease to lung cancer: towards stratified interception WEBSITE The project PREVALUNG EU will harness retrospective and prospective cohorts of both CVD patients and LCDT eligibles to develop actionable biomarkers and validate the four classifiers detecting high-risk individuals before or pre-symptomatic of LC, exploiting the latest advances of system biology omics (metabolomics, metagenomics, immunomics, proteomics, and aging-associated BM stem cell genomics) that correlate with uncontrolled inflammatory status of CVD patients. In particular, using four types of diagnosis tools harnessing either of the four drivers of overt inflammation (metabolism, gut dysbiosis, stem cell mutational status, innate immunity), we shall stratify the CVD patient population and leverage the PLCOm2012 risk score to better identify LC high-risk individuals. We will propose a personalized interceptive measure, whose efficacy will be monitored using PREVALUNG EU Focus Panels. We will robustly validate clinical applications, workflows, and tools for easy and broad adoption of the interceptive system across European public care centers and private stakeholders.

Learning Hub Explore resources to help you understand and manage psoriatic arthritis. Learning hub Key Facts Handbook News Feed Quizzes Search Psoriatic Arthritis Key Facts keyfacts 1 Understanding Psoriatic Arthritis Learn what psoriatic arthritis is, how it’s connected to psoriasis, what symptoms to look out for, how it’s diagnosed, and how to recognise a flare. f1.1 f1.2 See related Handbook section See related Handbook section See related Handbook section See related Handbook section See related Handbook section f1.3 f1.5 F1.4 keyfacts 2 Managing Psoriatic Arthritis: Treatments and Lifestyle Learn how psoriatic arthritis is treated through medications, non-pharmacological treatments, and everyday lifestyle choices that support health and wellbeing. See related Handbook section See related Handbook section See related Handbook section See related Handbook section See related Handbook section f2.1 f2.2 f2.3 f2.4 f2.5 keyfacts 3 Living with Psoriatic Arthritis Everyday tips for balancing work, improving sleep, managing fatigue, and supporting mental wellbeing. f3.1 See related Handbook section See related Handbook section See related Handbook section See related Handbook section f3.2 f3.3 f3.4 key facts 4 Intimacy, Reproductive Health and Family Life Understanding how psoriatic arthritis may affect relationships, sexual and reproductive health, and family planning decisions. See related Handbook section See related Handbook section See related Handbook section See related Handbook section f4.1 f4.2 f4.3 f4.4

We welcome your comments or questions about iPROLEPSIS project!​ Feel free to contact us by filling in the form to submit your comments or questions.​ Project coordinator Prof. Leontios Hadjileontiadis Project Coordinator Aristotle University of Thessaloniki Contact us We welcome your comments or questions about iPROLEPSIS! Please contact us by filling in the form below to submit your comments or questions. Ask your question or write a comment First name Last name Email Write a message I have read and agree to the Privacy policy SUBMIT Thanks for submitting! Please note that we will not give you medical advice. To discuss symptoms or conditions, please contact your physician or other health care provider.

Learning Hub Explore resources to help you understand and manage psoriatic arthritis. Learning hub Key Facts Handbook News Feed Quizzes Search Quizzes What is psoriatic arthritis? Take a Quiz What are the symptoms of psoriatic arthritis? Take a Quiz How is psoriatic arthritis treated? Drug treatments Take a Quiz How is psoriatic arthritis treated? Self-care and lifestyle Take a Quiz How will psoriatic arthritis affect me? Sleep and Fatigue Take a Quiz How will psoriatic arthritis affect me? Relationships and Family Planning Take a Quiz What causes psoriatic arthritis? Take a Quiz How is psoriatic arthritis diagnosed? Take a Quiz How is psoriatic arthritis treated? Non-pharmacological treatments Take a Quiz How will psoriatic arthritis affect me? Work Take a Quiz How will psoriatic arthritis affect me? Emotional wellbeing Take a Quiz

iProlepsis psoriatic arthritis project is a comprehensive multiscale model employing novel trustworthy AI-based analysis of multisource and heterogenous data. iPROLEPSIS project objectives and work packages Project aspires to shed light upon the health-to-PsA transition with a comprehensive multiscale / multifactorial PsA model employing novel trustworthy AI-based analysis of multisource and heterogenous (i.a., in-depth health, environmental, genetic, behavioral) data. Project objectives iPROLEPSIS consortium works on 7 ambitious key objectives in the field of Psoriatic Arthritis (PsA). PsA inflamation drivers Discover PsA inflammation drivers through AI-driven health, environmental and omics data mining. Role of mast cells Investigate the role of mast cells and features from non-invasive skin microvascular/joint imaging in inflammatory symptoms tracking. Personalised interventions Develop ICT-based personalised interventions to sustain or even improve quality-of-life. Co-creative ecosystem Co-create the iPROLEPSIS ecosystem with key stakeholders, following ethical, inclusive and trustworthy AI principles. Digital biomarkers Develop and validate objective digital biomarkers for tracking inflammatory symptoms and disease activity. Trustwothy AI models Build trustworthy AI models for personalised PsA risk prediction, early diagnosis and high disease activity prognosis. Digital health ecosystem Develop and clinically validate the iPROLEPSIS digital health ecosystem to empower persons with/at risk of PsA and healthcare professionals. Work packages The 6 Work Packages of the project will bring together various and complementary expertise from consortium partners. WP1 WP2 WP3 WP4 WP5 WP6 Work Package 1: Management and coordination WP1 is dedicated to project management and coordination aiming to enable a smooth project workflow; Ensure optimal contractual, administrative, financial, scientific, technical, IP and innovation management; Assure project quality and safeguard ethics, regulatory compliance and proper data management. Work Package 2: Knowledge mining, foundation and participatory design WP2 aims to create a foundational body of knowledge concerning PsA, associated conditions and inflammation; Identify, retrieve and curate datasets relevant to R&D activities of the project; Identify user needs and effectively engage with key stakeholders for steering research questions and co-creating the iPROLEPSIS digital care tools; Establish and monitor practices for ensuring adherence of iPROLEPSIS AI-driven components to trustworthy AI principles. Work Package 3: Research on PsA inflammation drivers and monitoring WP3 is dedicated to identify drivers related to PsA and associated inflammation leveraging new and existing multi-source health relevant data; Develop smartphone/wearable-based digital biomarkers (dBMs) for assessing PsA inflammatory symptoms; Shed light on changes in the joints and skin microvasculature related to PsA and the role of mast cells in associated inflammation; Through data fusion, develop a multiscale/multifactorial PsA model, emphasising on the prediction of the transition of high-risk individuals and PsO patients to PsA and of PsA patients to advanced inflammatory state. Work Package 4: Development of the iPROLEPSIS digital health ecosystem for personalised preventive care WP4 will technically specify the iPROLEPSIS ecosystem and set up a robust data management infrastructure and DevOps/MLOps platforms; Through an agile approach, develop the iPROLEPSIS minimum viable products (MVPs) for personalised PsA care including: 1) the patient app incorporating (dBM-based)PsA monitoring, knowledge, targeted interventions and tailored AI-driven lifestyle recommendations, 2) the serious gaming suite for health and wellness, 3) the app for HCPs allowing them to remotely monitor patients and view predictions on their course. Work Package 5: Clinical studies WP5 will develop the study protocols and carry out the process for their timely approval by concerned bodies; Set up a system for coordinating recruitment and efficiently managing clinical data and reporting; Organise and conduct four clinical studies: two multicentre prospective cohort studies for discovery and validation of PsA inflammation drivers and digital biomarkers, one observational study on PsA and changes in the joints and skin microvasculature, and one multicentre proof-of-concept randomised controlled trial (RCT) evaluating the effectiveness of the iPROLEPSIS digital care tools. Work Package 6: Dissemination, communication and exploitation WP6 will maximise visibility of the project and its outcomes and facilitate knowledge exchange while engaging a wide network of stakeholders; Develop PsA-related educational content; Set out a roadmap for regulatory approval of the iPROLEPSIS digital tools; Perform a thorough socio-economic/market analysis and develop concrete joint/individual exploitation plans. PROJECT VISION

The consortium of iProlepsis project for psoriatic arthritis consists of 15 partners from 9 countries. Discover more about project by visiting our website. About consortium partners iPROLEPSIS project coordinator Aristotle University of Thessaloniki Consortium consists of 15 partners from 9 countries. iPROLEPSIS consortium partners

Learn more about international events for psoriatic arthritis. Choose the event and book the date. Upcoming and past events iPROLEPSIS 7th Plenary meeting Dec 09, 2025, 9:00 AM – Dec 10, 2025, 4:00 PM Lisbon, Lisbon, Portugal More info LEARN MORE IEEE HealthCom 2025 Oct 21, 2025, 9:00 AM – 7:30 PM Abu Dhabi, United Arab Emirates More info Details HLTH Event 2025 Oct 19, 2025, 9:00 AM – Oct 22, 2025, 6:00 PM Las Vegas, Las Vegas, NV, USA More info Details GRAPPA Annual Meeting 2025 Jul 10, 2025, 11:00 AM – Jul 12, 2025, 8:00 PM Bogota, Colombia More info Details iPROLEPSIS 6th Plenary meeting May 13, 2025, 11:00 AM – May 14, 2025, 5:00 PM Oxford, UK More info Details 7th Polythematic Panhellenic Congress of Autoimmune Diseases, Rheumatology and Clinical Immunology Mar 28, 2025, 10:00 AM – Mar 30, 2025, 8:00 PM Portaria, Pelion More info Details Health Data Summit 2025 Mar 19, 2025, 9:00 AM – Mar 20, 2025, 7:00 PM The EGG, Brussels, Belgium More info Details iPROLEPSIS 5th Plenary Meeting Dec 02, 2024, 7:00 AM – Dec 03, 2024, 5:00 PM Athens, Greece More info Details DSAI 2024 Nov 13, 2024, 7:00 AM – Nov 15, 2024, 5:00 PM Khalifa University, Abu Dhabi, United Arab Emirates (UAE) More info Details PhD Open Days 2024 - 10th edition Nov 05, 2024, 7:00 PM – 11:00 PM Lisbon, Portugal More info Details How to communicate about and disseminate project results under Horizon Europe Cluster 1 ‘Health’ and Horizon 2020 Oct 24, 2024, 12:00 PM – 1:00 PM GMT+3 Webinar More info Details 16th Panhellenic EPEMY Conference Oct 05, 2024, 8:00 AM – Oct 06, 2024, 6:00 PM Ioannina, Greece More info DETAILS Psoriatic Arthritis Awareness Day Sep 28, 2024, 8:00 AM – 11:50 PM Virtual More info DETAILS European Researchers’ Night Sep 27, 2024, 8:00 AM – 7:40 PM Lisbon, Portugal More info DETAILS InnoHealth Forum 2024 Sep 20, 2024, 8:00 AM – Sep 21, 2024, 6:00 PM Larissa, Greece More info DETAILS IEEE EMBC 2024 Jul 15, 2024, 8:00 AM – Jul 19, 2024, 6:00 PM Orlando, Florida, USA More info DETAILS iPROLEPSIS 4th Plenary meeting Jul 01, 2024, 8:00 AM – Jul 02, 2024, 6:00 PM Munich, Germany More info DETAILS IFPA Conference 2024 Jun 27, 2024, 8:00 AM – Jun 29, 2024, 4:00 PM Stockholm, Sweden More info DETAILS Load More

Download iProlepsis project applications for psoriatic arthritis. Apps for download miPROLEPSIS app The miPROLEPSIS app facilitates the iPROLEPSIS-PDPID multicenter clinical study as a data collection tool that will enable the development of digital biomarkers for psoriatic arthritis symptoms and predictive models for inflammation exacerbation. More specifically, the app performs (i) passive data collection from the sensors of the smartwatch used in the study (i.e., Garmin Vivoactive 5), (ii) passive data collection from the accelerometer and gyroscope sensors of the smartphone, (iii) patient reported outcomes via questionnaires. Moreover, the app includes (i) a custom keyboard that captures the user’s typing dynamics and (ii) photo- and video-based activities for the collection of hand/feet photos and skeletal data related to joints flexibility, respectively. Note: The app can be used only by psoriatic arthritis patients that have enrolled to the PDPID study. This enrollment is available for patients in the UK, Netherlands, Portugal, and Greece. Information on how to enroll in the study and gain access to the miPROLEPSIS app will be provided soon. miPROLEPSIS app The miPROLEPSIS PDPID Study application functions as a data collection tool, utilized during the PDPID study, in order to produce datasets used for model generation and training. The app utilises both continuous and unobtrusive data collection (via bluetooth) from wearable devices, as well as user interactions (questionnaires, reporting etc). miPROLEPSIS Joint Landmarker app The miPROLEPSIS Joint Landmarker is an accompanying app of the miPROLEPSIS app that enables the video-based active tests feature. More specifically, a set of 6 hand and body movement exercises are presented and the user is asked to perform them in front of the smartphone camera. The app captures the videos and extracts skeletal data (coordinates of skeletal joints) locally. The skeletal data will be further analysed to develop digital biomarkers that assess the functionality and flexibility of joints. Note: The miPROLEPSIS Joint Landmarker app cannot be used without the miPROLEPSIS app. miPROLEPSIS Joint Landmarker app This app is a research app that accompanies the miPROLEPSIS app and aims to assess the physical functioning of people with Psoriatic Arthritis. More specifically, a set of 6 hand and body exercises are given and the user is asked to perform them in front of the smartphone camera. The app uses the collected videos to extract skeletal data (coordinates of skeletal joints), which are then sent to a cloud for further processing. Through the skeletal data processing, the aim is to identify whether a patient with Psoriatic Arthritis have difficulties in performing certain hand and body actions. The videos are immediately discarded and no personal information is retained, saved or transmitted.

iPROLEPSIS project will perform four different clinical studies in four different counties. Learn more about clinical studies by visiting iprolepsis.eu. About clinical studies iPROLEPSIS will perform four different clinical studies: 1. iPROLEPSIS-PDPID PsA digital phenotyping and inflammation drivers study. 2. iPROLEPSIS-MOJMI Mast cells and optoacoustics-enabled joint and microvascular imaging study. 3. iPROLEPSIS-IDBV Inflammation digital biomarkers validation study. 4. iPROLEPSIS-PPIDC Prevention of PsA inflammation through digital care: an intervention study. Clinical studies will be conducted in 5 countries: Netherlands UK Portugal Greece Germany Clinical studies PsA digital phenotyping and inflammation drivers study (iPROLEPSIS-PDPID) Development cohort of smartphone and smartwatch-based, AI-driven digital biomarkers for remote assessment and monitoring of people with psoriatic arthritis. Measure To develop novel smartphone- and smart device (belt, ring, camera) digital biomarkers for the assessment of inflammatory symptoms with special focus on the recognition of changes in movement patterns, pain, fatigue, morning stiffness in comparison to the gold standard – medical evaluation by clinical evaluation of the joints, tendons and skin. Predict To predict the change from uninflamed to inflamed using three triggers that may cause longstanding inflammation in psoriatic arthritis patients at risk for flare. Those three triggers are stress, mechanical stress and changes in the gut microbiome. OBJECTIVES Primary objectives to provide accurate, factual and clinically relevant records of the self-contained smartphone and smartwatch[1] based, AI-driven digital biomarker system in the detection of PsA specific inflammation; to predict accurate, factual and clinically relevant PsA specific inflammation. Secondary objectives to determine interperson reliability of the AI-driven digital biomarker system; to determine construct validity against clinical assessment of inflammation; to determine construct validity against patient assessment of inflammation; to determine clinically relevant changes in the AI-driven digital biomarker system; to determine minimal detectable difference in the AI-driven digital biomarker system; to assess the interperson variation of stress, mechanical stress and changes in gut microbiome on the occurrence of inflammation; to evaluate the compliance and satisfaction of the users with the smartphone and smartwatch-based, AI[1] driven digital monitoring system. The study is designed to develop a new way of measuring inflammation in patient with psoriatic arthritis. Definition of novel optoacoustic biomarkers of psoriasis and psoriatic arthritis (iPROLEPSIS-MOJMI) Mast cells and optoacoustics-enabled joint and microvascular imaging (iPROLEPSIS-MOJMI) study. The proposed multiscale (mesoscopic with RSOM and macroscopic with MSOT) approach aims at exploring and defining novel image-based biomarkers in order to describe the pathophysiological changes characterizing the disease and predict the transition from PsO to PsA. In other words, the unique multiscale nature of optoacoustics is expected to render skin microvasculature a window to later systemic (joint) effects of psoriasis and, thus, improve the prognosis in future patients with PsO. OBJECTIVES Primary objectives To define novel inflammatory mast cell, MSOT- and RSOM extracted biomarkers in patients with PsO/PsA. To quantify the changes of the novel inflammatory mast cell, MSOT- and RSOM-extracted biomarkers' with increasing disease severity. Secondary objectives To reveal correlations among the mast cells and the MSOT-and RSOM-extracted inflammatory biomarkers in patients with PsO/PsA. To define a novel index derived from mast cells, MSOT- and RSOM-based features to enable the early detection of PsA in patients with PsO or high risk for developing PsO. Inflammation digital biomarkers validation study (iPROLEPSIS-IDBV) Finding people that will convert from healthy to inflamed is a difficult task in Immune Mediated Inflammatory Disease (IMID). Initial symptoms look just like any other musculoskeletal disorder such as back pain, finger pain or achilles tendon problems. Over time symptoms can go either temporarily away, become chronic or become so severe that doctor care is needed. Early identification of people with IMID would greatly benefit their quality of live, keeps them at work and prevents high health care cost due to expensive medication. Digital biomarkers will give us for the first time the ability to study the conversion from musculoskeletal disorder to immune mediated inflammatory joint and tendon disease. The aim of this study to validate our digital biomarkers findings in PsA in psoriasis patients. OBJECTIVES Primary objectives to validate accurate, factual and clinically relevant records of the self-contained smartphone and smartwatch-based, AI-driven digital biomarker system in the detection of IMID specific joint or tendon inflammation. Secondary objectives to evaluate take up and acceptability of the digital biomarker in the wild; to evaluate the impact of missing data in detecting inflammation; to assess the number of false positives when data is captured in the wild; to assess the interperson variation of stress and mechanical stress. The aim is to identify inflammation with a software based medical device. This software will consist of an algorithm analysing data collected in the wild via smart devices: phone, watch, ring. Prevention of PsA inflammation through digital care: an intervention study (iPROLEPSIS-PPIDC) This study blends the findings of the newly developed digital biomarkers, the early findings of the triggers: stress, mechanical stress and changes in microbiome from PsA digital phenotyping and inflammation drivers study (iPROLEPSIS-PDPID), to provide a personalised approach to deal with the triggers with state-of-the-art interventions. OBJECTIVES Primary objectives In PsA patients with low disease activity a personalised intervention on food, physical activity and stress based on a personal profile of stress, mechanical stress and microbiome will be compared to usual care on inflammation development as detected by the newly developed digital biomarker system and clinical examination. Secondary objectives to evaluate take up and acceptability of the digital biomarker and intervention as part of normal medical treatment among patients, doctors and nurses; to assess compliance with the personalised intervention.

iPROLEPSIS project newsletter Nov 6, 2025 Issue No. 10 iPROLEPSIS project newsletter No 10 Welcome! This is the 10th edition of the iPROLEPSIS newsletter, where we share the latest updates and progress from the project. READ THE NEWSLETTER Jul 1, 2025 Issue No. 9 iPROLEPSIS project newsletter No 9 Welcome! This is the 9th edition of the iPROLEPSIS newsletter, where we share the latest updates and progress from the project. READ THE NEWSLETTER Apr 28, 2025 Issue No. 8 iPROLEPSIS project newsletter No 8 Welcome! This is the 8th edition of the iPROLEPSIS newsletter, where we share the latest updates and progress from the project. READ THE NEWSLETTER Jan 28, 2025 Issue No. 7 iPROLEPSIS project newsletter No 7 Welcome! This is the 7th edition of the Newsletter series of the iPROLEPSIS project. In this issue, we highlight the insights on the future of digital biomarkers in rheumatology care, offer key information about PsA and practical advice to improve daily life, update about past events. READ THE NEWSLETTER Oct 9, 2024 Issue No. 6 iPROLEPSIS project newsletter No 6 Welcome! This is the 6th edition of the Newsletter series of the iPROLEPSIS project. In this issue, we highlight the release of the miPROLEPSIS and miPROLEPSIS Joint Landmarker apps, recent publications, reflections on Psoriatic Arthritis Awareness Day and Psoriasis Awareness Month, and key takeaways from recent events. READ THE NEWSLETTER Jul 9, 2024 Issue No. 5 iPROLEPSIS project newsletter No 5 Welcome! This is the 5th edition of the Newsletter series of the iPROLEPSIS project. In this newsletter issue, we delve into the updates and progress of the project activities, synergies and events. READ THE NEWSLETTER Mar 7, 2024 Issue No. 4 iPROLEPSIS project newsletter No 4 Welcome! This is the 4th edition of the Newsletter series of the iPROLEPSIS project. Let's explore the latest developments and advancements in our project activities, collaborations, and upcoming events. READ THE NEWSLETTER Nov 30, 2023 Issue No. 3 iPROLEPSIS project newsletter No 3 Welcome! This is the 3rd edition of the Newsletter series of the iPROLEPSIS project. In this newsletter issue, we delve into the updates and progress of the project activities, synergies and events. READ THE NEWSLETTER Sep 5, 2023 Issue No. 2 iPROLEPSIS project newsletter No 2 Welcome! This is the 2nd edition of the Newsletter series of the iPROLEPSIS project. In this newsletter issue, we delve into the transformative power of user research and co-creation in the healthcare innovation research process. READ THE NEWSLETTER Jul 3, 2023 Issue No. 1 iPROLEPSIS project newsletter No 1 Welcome! This is the 1st edition of the newsletter series of the iPROLEPSIS project! The 1st newsletter informs you about the iPROLEPSIS project, its vision, pillars and objectives, and the partners involved. READ THE NEWSLETTER